RBC Capital Maintains Outperform on IGM Biosciences, Raises Price Target to $20

Benzinga · 10/18 12:27
RBC Capital analyst Brian Abrahams maintains IGM Biosciences (NASDAQ:IGMS) with a Outperform and raises the price target from $17 to $20.